Meeting
2011 ASCO Annual Meeting
Impact of carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer (DRPC) on free testosterone levels.
Authors
C. W. Reuter
Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
C. W. Reuter , M. A. Morgan , M. Fenner , P. Ivanyi , V. Gruenwald , A. Ganser
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer
Track
Genitourinary Cancer
Sub Track
Prostate Cancer
Citation
J Clin Oncol 29: 2011 (suppl; abstr 4593)
Abstract #
4593
Poster Bd #
4A
Abstract Disclosures
Similar Posters
Poster
2014 Genitourinary Cancers Symposium
Salvage chemotherapy with carboplatin plus weekly docetaxel in patients (pts) with castration- and docetaxel-resistant prostate cancer (DRPC): Associations of patient and disease characteristics with overall survival (OS).
First Author: Christoph W. Reuter
Poster
2016 ASCO Annual Meeting
Prognostic significance of free testosterone levels during chemotherapy with carboplatin plus docetaxel (CD) in metastatic castration- and docetaxel-resistant prostate cancer (mDRPC).
First Author: Christoph W. Reuter
Poster
2014 ASCO Annual Meeting
Prognostic value of free testosterone (FT) levels during salvage chemotherapy with carboplatin plus weekly docetaxel in metastatic castration- and docetaxel-resistant prostate cancer (mDRPC).
First Author: Christoph W. Reuter
Poster
2017 ASCO Annual Meeting
Prognostic value of free testosterone (FT) levels during chemotherapy with carboplatin plus weekly docetaxel in metastatic castration- and docetaxel-resistant prostate cancer (mDRPC).
First Author: Christoph Reuter